Skip to main content
OpenTrials
Completed

NCT Number: NCT04886908

Comparative Retrospective Analysis of Skin Tumors of the Eyelids and Face in 2 Brussels University Hospitals Over 5 Years in Dermatology or Ophthalmology

Skin cancers are the most common of all cancers. Their incidence has increased sharply over the decades.This increase in incidence partly reflects an aging population and behavioral patterns such as repeated exposure to the sun. Indeed, exposure to UV rays is the predominant factor involved in the pathogenesis of these tumors, hence the fact that they mainly develop in photo-exposed regions such as the cephalic extremity.

The objective of this study is to provide an epidemiological analysis of tumors in the populations of both CHU Brugmann and St Pierre hospitals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Cancer Neoplasms Neoplasms by Site Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Brugmann

Brussels, 1020, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Final diagnosis confirmed by pathological analysis, epidemiological and clinical information available from patients.

Exclusion criteria

Patients who have expressed a refusal to access their medical file or incomplete data will not be taken into account.

Treatment and study plan

Data extraction from medical files

Other

Data extraction from medical files

Primary outcomes

  1. Age

    Time frame: 5 minutes

    Age of the patient at the time of diagnose

  2. Sex

    Time frame: 5 minutes

    Sex of the patient

  3. Name of the department in which the patient is followed

    Time frame: 5 minutes

    Ophthalmology-CHU Brugmann hospital or Dermatology-CHU Brugmann hospital or Ophthalmology- CHU St Pierre Hospital or Dermatology-CHU St Pierre Hospital

  4. Tumor anatomical location

    Time frame: 5 minutes

    Eyelids are distributed in their different regions: internal cantus and external cantus, upper eyelid and lower eyelid. Same for the face: ears, zygomatic, forehead, temples, cheeks, nose, upper lip, lower lip, chin, nasolabial fold, preauricular area, retroauricular area, brow bone.

  5. Tumor size

    Time frame: 5 minutes

    Tumor size in millimeters

  6. Laterality

    Time frame: 5 minutes

    Laterality: left, right, median

  7. Multiple or single tumor

    Time frame: 5 minutes

    Multiple or single tumor

  8. Primitive tumor or recidive

    Time frame: 5 minutes

    Primitive tumor or recidive

  9. Risk factor: phototype

    Time frame: 5 minutes

    Phototype 1 to 6 on the Fitzpatrick scale. The Fitzpatrick scale is a numerical classification schema for human skin color. Type 1 is pale skin that always burns, never tans and type 6 is deeply pigmented dark brown to darkest brown skin that never burns.

  10. Risk factor: immunosuppression (yes/no)

    Time frame: 5 minutes

    Pathogenic or iatrogenic, history of malignant skin tumors other than melanoma, personal or family history of melanoma

  11. Risk factor: keratosis

    Time frame: 5 minutes

    Actinic keratosis of the face

  12. Risk factor: solar exposition (yes/no)

    Time frame: 5 minutes

    Lived in a sunny European country> 1 year, lived in a sunny country outside Europe> 1 year, sunbed use> 1 session, history of solar erythema during childhood.

  13. Diagnosis

    Time frame: 5 minutes

    Time between the appearance of the tumor and the first consultation

  14. Locoregional extension report (yes/no)

    Time frame: 5 minutes

    Locoregional extension report (yes/no)

  15. Histological diagnosis of the tumor

    Time frame: 5 minutes

    Histological diagnosis of the tumor

  16. Healthy or invaded margins

    Time frame: 5 minutes

    Healthy or invaded margins

  17. Superficial or infiltrating tumor

    Time frame: 5 minutes

    Superficial or infiltrating tumor

  18. Diagnostic method

    Time frame: 5 minutes

    Diagnostic method: curettage, punch, biopsy, flattening

  19. Surgical management method

    Time frame: 5 minutes

    Biopsy resection, plasty, graft, second-line healing, enucleation, additional treatment: radiotherapy, immunotherapy, liquid nitrogen

Sponsors and collaborators

Lead sponsor

Brugmann University Hospital

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
May 14, 2021
Registry last updated
Mar 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.